Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may
stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether
interferon alfa plus combination chemotherapy and interleukin-2 is more effective than
interferon alfa alone in treating patients with melanoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or
without combination chemotherapy plus interleukin-2 in treating patients with melanoma.